Status:

COMPLETED

Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects

Lead Sponsor:

Nantes University Hospital

Conditions:

Gastroesophageal Reflux

Eligibility:

All Genders

18-55 years

Phase:

PHASE2

Brief Summary

This study aims to determine, in obese subjects, the antisecretory effect of a single dose of placebo, rabeprazole 20 mg and omeprazole 20 mg using 24h gastric pH monitoring, in a prospective, monocen...

Eligibility Criteria

Inclusion

  • Helicobacter negative obese subject (BMI 30 to 40),
  • 18 to 55 years old,
  • normal hepatic biology and morphology (echography)
  • Contraceptive methods in women.

Exclusion

  • Subjects with previous abdominal surgery, with diabetic or immunosuppressive treatment.

Key Trial Info

Start Date :

April 1 2010

Trial Type :

INTERVENTIONAL

End Date :

July 1 2010

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01136317

Start Date

April 1 2010

End Date

July 1 2010

Last Update

September 24 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU de Nantes

Nantes, France, 44093

Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects | DecenTrialz